Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial

Official title:

A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00363272
• Other study ID #: NCI-2012-01828
• Secondary ID: ADVL0517U01CA097
• Status: Completed
• Phase: Phase 1
• First received: August 10, 2006
• Last updated: January 15, 2013
• Start date: June 2006

Study information

• Verified date: January 2013
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma. Drugs used in chemotherapy, such as ispinesib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

Description:

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose and recommended phase II dose of ispinesib in pediatric patients with refractory solid tumors or lymphoma.

II. Define and describe the toxicities of ispinesib in these patients. III. Characterize the pharmacokinetics of ispinesib in these patients.

SECONDARY OBJECTIVES:

I. Define, preliminarily, the antitumor activity of ispinesib. II. Determine the relationship between CYP3A4 gene polymorphisms and pharmacokinetics in patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of ispinesib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients undergo blood and tumor sample collection periodically for pharmacokinetic and gene polymorphism correlative studies.

After completion of study therapy, patients are followed for 30 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year to 21 Years

Eligibility

Inclusion Criteria:

• Histologically confirmed malignancy at either original diagnosis or relapse, including the following:

• Solid tumor, including primary CNS tumors

• Neurologic deficits in patients with CNS tumors must have been relatively stable for = 1 week

• Patients with CNS tumors must be on stable or decreasing doses of dexamethasone for the past 7 days

• Histology requirement waived for intrinsic brain stem tumors

• Lymphoma

• Measurable or evaluable disease

• No known curative therapy or no therapy proven to prolong survival with an acceptable quality of life exists

• Patients with known bone marrow metastases are eligible for study but are not evaluable for hematologic toxicity

• Not known to be refractory to red blood cell or platelet transfusions

• Karnofsky performance score (PS) 60-100% (> 10 years of age) or Lansky PS 60-100% (= 10 years of age)

• Absolute neutrophil count = 1,000/mm³

• Platelet count = 100,000/mm³ (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to study enrollment)

• Hemoglobin = 8.0 g/dL (RBC transfusions allowed)

• Creatinine clearance or radioisotope glomerular filtration rate = 70 mL/min OR creatinine based on age as follows:

• No greater than 0.8 mg/dL (= 5 years of age)

• No greater than 1.0 mg/dL (6 to 10 years of age)

• No greater than 1.2 mg/dL (11 to 15 years of age)

• No greater than 1.5 mg/dL (> 15 years of age)

• Bilirubin = 1.5 times upper limit of normal

• ALT = 45 U/L

• Albumin = 2 g/dL

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No evidence of active graft-vs-host disease

• No uncontrolled infection

• Recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy

• More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)

• More than 1 week since prior growth factors, including those that support platelet or WBC number or function

• At least 1 week since prior biologic agents

• At least 2 weeks since prior local, palliative, small-port external-beam radiotherapy

• At least 6 months since prior total body irradiation (TBI), craniospinal radiotherapy, or radiotherapy to = 50%of the pelvis

• At least 6 weeks since other prior substantial bone marrow radiotherapy (i.e., skull, spine, pelvis, or ribs)

• At least 3 months since prior stem cell transplantation or rescue without TBI

• No other concurrent investigational drugs

• No other concurrent anticancer agents, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy

• No concurrent enzyme-inducing anticonvulsants, including any of the following:

• Phenytoin

• Phenobarbital

• Felbamate

• Primdone

• Oxcarbazepine

• Carbamazepine

• No concurrent agents that inhibit CYP3A4, including any of the following:

• Itraconazole

• Ketoconazole

• Voriconazole

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Astrocytoma
• Brain Neoplasms
• Burkitt Lymphoma
• Childhood Burkitt Lymphoma
• Childhood Central Nervous System Germ Cell Tumor
• Childhood Choroid Plexus Tumor
• Childhood Craniopharyngioma
• Childhood Grade I Meningioma
• Childhood Grade II Meningioma
• Childhood Grade III Meningioma
• Childhood High-grade Cerebral Astrocytoma
• Childhood Infratentorial Ependymoma
• Childhood Low-grade Cerebral Astrocytoma
• Childhood Spinal Cord Neoplasm
• Childhood Supratentorial Ependymoma
• Choroid Plexus Neoplasms
• Craniopharyngioma
• Ependymoma
• Glioma
• Lymphoma
• Lymphoma, Extranodal NK-T-Cell
• Lymphoma, Non-Hodgkin
• Lymphomatoid Granulomatosis
• Medulloblastoma
• Meningioma
• Neoplasms
• Neuroectodermal Tumors
• Neuroectodermal Tumors, Primitive
• Optic Nerve Glioma
• Recurrent Childhood Brain Stem Glioma
• Recurrent Childhood Brain Tumor
• Recurrent Childhood Cerebellar Astrocytoma
• Recurrent Childhood Cerebral Astrocytoma
• Recurrent Childhood Ependymoma
• Recurrent Childhood Grade III Lymphomatoid Granulomatosis
• Recurrent Childhood Large Cell Lymphoma
• Recurrent Childhood Lymphoblastic Lymphoma
• Recurrent Childhood Medulloblastoma
• Recurrent Childhood Small Noncleaved Cell Lymphoma
• Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
• Recurrent Childhood Visual Pathway and Hypothalamic Glioma
• Spinal Cord Neoplasms
• Unspecified Childhood Solid Tumor, Protocol Specific

Intervention

Drug:
• ispinesib
Given IV

Other:
• laboratory biomarker analysis
Correlative studies
• pharmacological study
Correlative studies

Locations

Country	Name	City	State
United States	Children's Oncology Group	Arcadia	California

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose, defined as the maximum dose at which fewer than one-third of patients experience DLT, graded according to NCI CTCAE version 3.0		Up to 28 days	Yes